Pfizer is feeling the heat as thousands of pages of their COVID-19 vaccine data are set to be released to the public and the have begun scrambling to modify text to cover their own butts.
Pfizer has been caught changing the fine print, as evidenced by several changes in their Q4 earnings releases presented below, and quietly admitting that an audit or inspection of the “quality of pre-clinical, clinical, or safety data” could have a negative impact on their profit margins:
Pfizer seems to be preparing for some very bad news and doing a little bit of cover in preparation.
Two weeks agi, the FDA asked a Texas judge to postpone the release of the first monthly batch of 55,000 pages of Covid-19 vaccination data supplied to the agency by Pfizer. Initially, the firm was just supposed to create 500 pages every month.
As Rubicon Capital’s Kelly Brown writes on Twitter, the modifications to Pfizer’s earnings reports revolve around disclosures of adverse safety data.
In Q4, for example, they added: “or further information regarding the quality of pre-clinical, clinical or safety data, including by audit or inspection.”
Brown notes that Pfizer is now highlighting “concerns about clinical data integrity…“
The company also notes that Covid-19 may “diminish in severity or prevalence, or disappear entirely.”
So the question remains; what are they hiding?
